Pair page
BPC-157 with Livagen
Mechanism-tag overlap and published literature for BPC-157 and Livagen, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
khavinson-lymphoid-hepatic-bioregulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and Livagen have published these mechanism-level observations. Not a co-administration recommendation.
Gastric-derived pentadecapeptide with hepatoprotective and gut-protective preclinical signals. Mechanistically distinct from Livagen but layered in some gut-liver community protocols.
Quick facts
BPC-157
Livagen
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2021 | Livagen | Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. (Recent programmatic review of Khavinson peptide-DNA interaction framework.) PMID 34834147 | systematic review |
| 2011 | Livagen | Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID:… PMID 22117546 | preclinical, in vitro |
| 2015 | Livagen | Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). 2015;80(3):310-322. PMID: 25761685. PMID 25761685 | mechanism / discovery |
| 2007 | Livagen | Khavinson VKh. Tetrapeptide KEDA decondenses heterochromatin in hepatocyte nuclei and modulates liver gene expression. (Khavinson-group experimental work across Russian-language publications, 2007–2012, Bulletin of Experimental Biology and Medicine.) | mechanism / discovery |
| 2003 | Livagen | Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682. (Telomerase claim framework.) PMID 12937682 | mechanism / discovery |
| 2003 | Livagen | Khavinson VKh, Malinin VV, Myl'nikov SV. Effect of peptides on lifespan of animals and peptide-dependent gene expression. Bull Exp Biol Med. 2003;135(4):373-375. PMID: 12820081. PMID 12820081 | mechanism / discovery |
| 2021 | Livagen | Fedoreyeva LI, Vanyushin BF. Epigenetic Activity of Short Peptides and Their Interaction with Nucleic Acids. Biol Bull Rev. 2021;11:351-362. (Broader Khavinson-framework review of short-peptide chromatin interactions.) | review |
| 2002 | Livagen | Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374919. (Comprehensive review of the Khavinson short-peptide bioregulator framework, including KEDA / Livagen.) PMID 12374919 | review |
| 2010 | Livagen | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19730006. PMID 19730006 | bioregulator literature |
| 2005 | Livagen | Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger Publishers; 2005. ISBN 3-8055-7905-5. (Book-length monograph of the Khavinson framework.) | bioregulator literature |
| 2003 | Livagen | Khavinson VKh, Lezhava TA, Monaselidze JR, Jokhadze TA, Dvalishvili NA, Bablishvili NK, Trofimova SV. Peptide Epitalon activates chromatin at the old age. Neuroendocrinol Lett. 2003;24(5):329-333. PMID: 14647006. (Chromatin activation framework; Epithalon but same mechanistic fr… PMID 14647006 | bioregulator literature |
| 2003 | Livagen | Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. PMID 14523363 | bioregulator literature |
Related pair pages
More research context
Frequently asked
Have BPC-157 and Livagen been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and Livagen. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and Livagen share?
BPC-157 and Livagen do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and Livagen?
BPC-157: Category 2 (reclassification pending). Livagen: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and Livagen?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the Livagen profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026